Aditxt, Inc. Operating Lease, Expense
Aditxt, Inc. (ADTX) reported Operating Lease, Expense of $305.05 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-05-20
- Aditxt, Inc. operating lease, expense for the quarter ending 2024-03-31 was $305.05K, a 2.68% increase year-over-year.
- Aditxt, Inc. operating lease, expense for the quarter ending 2023-12-31 was $177.74K, a 56.49% decline year-over-year.
- Aditxt, Inc. operating lease, expense for the quarter ending 2023-09-30 was $366.65K, a 9.46% increase year-over-year.
- Aditxt, Inc. operating lease, expense for the quarter ending 2023-06-30 was $299.47K, a 9.50% decline year-over-year.
- Aditxt, Inc. operating lease, expense for fiscal 2023 was $1.14M, a 18.32% decline from fiscal 2022.
- Aditxt, Inc. operating lease, expense for fiscal 2022 was $1.40M, a 70.44% increase from fiscal 2021.
- Aditxt, Inc. operating lease, expense for fiscal 2021 was $819.59K, a 431.29% increase from fiscal 2020.
- Aditxt, Inc. operating lease, expense for fiscal 2020 was $154.26K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $305.05K 10-Q · filed 2024-05-20 | $482.79K derived: sum of 2 quarters · filed 2024-05-20 | $849.44K derived: sum of 3 quarters · filed 2024-05-20 | $1.15M derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-12-31 | $177.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $544.39K derived: sum of 2 quarters · filed 2024-04-16 | $843.86K derived: sum of 3 quarters · filed 2024-04-16 | $1.14M 10-K · filed 2024-04-16 |
| 2023-09-30 | $366.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $666.12K derived: sum of 2 quarters · filed 2023-11-14 | $963.21K 10-Q · filed 2023-11-14 | $1.37M derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-06-30 | $299.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $596.56K 10-Q · filed 2023-08-14 | $1.01M derived: sum of 3 quarters · filed 2024-05-20 | $1.34M derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-03-31 | $297.09K 10-Q · filed 2024-05-20 | $705.59K derived: sum of 2 quarters · filed 2024-05-20 | $1.04M derived: sum of 3 quarters · filed 2024-05-20 | $1.37M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $408.49K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $743.47K derived: sum of 2 quarters · filed 2024-04-16 | $1.07M derived: sum of 3 quarters · filed 2024-04-16 | $1.40M 10-K · filed 2024-04-16 |
| 2022-09-30 | $334.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $665.89K derived: sum of 2 quarters · filed 2023-11-14 | $988.38K 10-Q · filed 2023-11-14 | $1.29M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $330.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $653.41K 10-Q · filed 2023-08-14 | $957.04K derived: sum of 3 quarters · filed 2023-08-14 | $1.21M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $322.50K 10-Q · filed 2023-05-15 | $626.13K derived: sum of 2 quarters · filed 2023-05-15 | $882.79K derived: sum of 3 quarters · filed 2023-05-15 | $1.02M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $303.63K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $560.29K derived: sum of 2 quarters · filed 2023-04-17 | $694.97K derived: sum of 3 quarters · filed 2023-04-17 | $819.59K 10-K · filed 2023-04-17 |
| 2021-09-30 | $256.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $391.34K derived: sum of 2 quarters · filed 2022-11-14 | $515.96K 10-Q · filed 2022-11-14 | $623.52K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $134.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $259.29K 10-Q · filed 2022-08-15 | $366.86K derived: sum of 3 quarters · filed 2022-08-15 | $410.43K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $124.61K 10-Q · filed 2022-05-16 | $232.18K derived: sum of 2 quarters · filed 2022-05-16 | $275.75K derived: sum of 3 quarters · filed 2022-05-16 | $271.16K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $107.56K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $151.14K derived: sum of 2 quarters · filed 2022-03-31 | $146.54K derived: sum of 3 quarters · filed 2022-03-31 | $154.26K 10-K · filed 2022-03-31 |
| 2020-09-30 | $43.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $38.98K derived: sum of 2 quarters · filed 2021-11-15 | $46.70K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$4.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $3.13K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $7.72K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |